Personalized cancer vaccine trial for rare skin cancer withdrawn before starting
NCT ID NCT05799612
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to find a safe dose of a custom-made mRNA vaccine for people with a rare skin cancer called cutaneous angiosarcoma. The vaccine was designed to train the immune system to attack the cancer. However, the trial was withdrawn before any participants were enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill may keep soft tissue sarcoma in check after chemo
- New combo therapy aims to shrink sarcomas
- New Two-Drug immune attack launched against tough cancers
- New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
- New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
- New hope for rare cancers? drug combo shows promise in early trial